Korsana Biosciences launched with $175 million in financing to develop an anti‑amyloid antibody, KRSA‑028, targeting delivery across the blood‑brain barrier. The company plans a 2027 clinical start and aims to position its candidate amid already‑approved and investigational amyloid‑clearing antibodies. Investors including Fairmount and Venrock backed the debut, reflecting persistent venture interest in high‑stakes Alzheimer’s programs despite a crowded field. Korsana’s plan emphasizes antibody engineering and brain delivery strategies; detailed preclinical and biomarker plans will determine whether the program differentiates from existing agents.